This target trial emulation compared adults with type 2 diabetes starting SGLT2 inhibitors or metformin as first-line therapy. Records from a global research network gave 36,720 propensity-matched pairs of new users, 2018 to 2023. SGLT2 inhibitor initiation was associated with lower risk of major adverse cardiovascular events (HR 0.88) and all-cause mortality (HR 0.73). Risks of stroke (HR 0.84), cardiac arrest (HR 0.81) and acute heart failure (HR 0.94) were also lower. Myocardial infarction (HR 0.97) and kidney failure needing replacement therapy (HR 1.00) did not differ. The design is observational, and median follow-up was shorter for SGLT2 inhibitors (2.5 years) than for metformin (3.5 years).
Why it is interesting: The study compares two first-line drugs in type 2 diabetes head to head. SGLT2 inhibitors were linked to fewer deaths, but not to fewer heart attacks or kidney failures.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.